| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiomyopathies | 20 | 2026 | 300 | 4.590 |
Why?
|
| Heart Failure | 51 | 2026 | 1376 | 4.000 |
Why?
|
| Amyloid Neuropathies, Familial | 16 | 2026 | 44 | 3.890 |
Why?
|
| Heart-Assist Devices | 42 | 2025 | 883 | 3.440 |
Why?
|
| Amyloidosis | 16 | 2026 | 132 | 3.000 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 9 | 2026 | 29 | 1.630 |
Why?
|
| Hemodynamics | 19 | 2025 | 712 | 1.610 |
Why?
|
| Prealbumin | 13 | 2026 | 45 | 1.590 |
Why?
|
| Heart Transplantation | 10 | 2026 | 814 | 1.210 |
Why?
|
| Ventricular Function, Left | 15 | 2025 | 517 | 1.170 |
Why?
|
| Echocardiography | 12 | 2026 | 748 | 1.150 |
Why?
|
| Pulmonary Wedge Pressure | 10 | 2021 | 117 | 0.850 |
Why?
|
| Heart Ventricles | 10 | 2024 | 649 | 0.720 |
Why?
|
| Cardiac Catheterization | 10 | 2019 | 295 | 0.700 |
Why?
|
| Heart Valve Diseases | 3 | 2024 | 100 | 0.660 |
Why?
|
| Middle Aged | 62 | 2026 | 27535 | 0.650 |
Why?
|
| Diflunisal | 1 | 2020 | 1 | 0.650 |
Why?
|
| Male | 69 | 2026 | 44355 | 0.610 |
Why?
|
| Intra-Aortic Balloon Pumping | 5 | 2024 | 92 | 0.600 |
Why?
|
| Humans | 92 | 2026 | 93132 | 0.590 |
Why?
|
| Aged | 48 | 2026 | 20395 | 0.580 |
Why?
|
| Female | 66 | 2026 | 48542 | 0.550 |
Why?
|
| Retrospective Studies | 33 | 2026 | 10128 | 0.540 |
Why?
|
| Prospective Studies | 16 | 2025 | 4546 | 0.400 |
Why?
|
| Postoperative Complications | 7 | 2026 | 2552 | 0.390 |
Why?
|
| Prosthesis Implantation | 3 | 2019 | 133 | 0.380 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2021 | 128 | 0.380 |
Why?
|
| Treatment Outcome | 21 | 2026 | 9070 | 0.360 |
Why?
|
| Benzoic Acid | 3 | 2026 | 3 | 0.360 |
Why?
|
| Graft Rejection | 3 | 2026 | 1123 | 0.350 |
Why?
|
| Transplant Recipients | 2 | 2025 | 159 | 0.350 |
Why?
|
| Immunoglobulin Light Chains | 3 | 2026 | 66 | 0.340 |
Why?
|
| Pyrazoles | 3 | 2026 | 152 | 0.330 |
Why?
|
| Ventricular Dysfunction, Left | 3 | 2024 | 258 | 0.310 |
Why?
|
| Shock, Cardiogenic | 2 | 2021 | 168 | 0.310 |
Why?
|
| Coronary Artery Bypass | 3 | 2020 | 223 | 0.300 |
Why?
|
| Azithromycin | 1 | 2009 | 16 | 0.290 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 7039 | 0.290 |
Why?
|
| Predictive Value of Tests | 9 | 2026 | 1703 | 0.290 |
Why?
|
| Drug Hypersensitivity | 1 | 2009 | 38 | 0.290 |
Why?
|
| Mitral Valve Insufficiency | 2 | 2024 | 175 | 0.280 |
Why?
|
| Myocarditis | 1 | 2009 | 59 | 0.280 |
Why?
|
| Echocardiography, Doppler | 3 | 2018 | 134 | 0.280 |
Why?
|
| Prognosis | 10 | 2026 | 3890 | 0.270 |
Why?
|
| Pacemaker, Artificial | 2 | 2020 | 108 | 0.270 |
Why?
|
| Thromboembolism | 2 | 2018 | 122 | 0.260 |
Why?
|
| Device Removal | 2 | 2019 | 166 | 0.260 |
Why?
|
| Thrombosis | 2 | 2020 | 308 | 0.260 |
Why?
|
| Waiting Lists | 2 | 2025 | 211 | 0.250 |
Why?
|
| Benzoxazoles | 2 | 2024 | 3 | 0.240 |
Why?
|
| Hemorrhage | 2 | 2018 | 289 | 0.240 |
Why?
|
| Hematology | 1 | 2026 | 32 | 0.240 |
Why?
|
| Stroke Volume | 4 | 2025 | 434 | 0.240 |
Why?
|
| Survival Rate | 7 | 2026 | 1945 | 0.240 |
Why?
|
| Cannula | 4 | 2019 | 54 | 0.230 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2018 | 239 | 0.230 |
Why?
|
| Follow-Up Studies | 9 | 2026 | 3814 | 0.230 |
Why?
|
| Body Composition | 1 | 2026 | 75 | 0.230 |
Why?
|
| Heart Function Tests | 2 | 2018 | 28 | 0.220 |
Why?
|
| Ventricular Function, Right | 3 | 2025 | 138 | 0.210 |
Why?
|
| Cardiotonic Agents | 2 | 2019 | 87 | 0.210 |
Why?
|
| Cardiac Output | 3 | 2022 | 141 | 0.210 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2017 | 332 | 0.200 |
Why?
|
| Registries | 2 | 2026 | 995 | 0.200 |
Why?
|
| Cardiac Valve Annuloplasty | 1 | 2023 | 15 | 0.200 |
Why?
|
| Biomarkers | 6 | 2026 | 1905 | 0.200 |
Why?
|
| Atrioventricular Block | 1 | 2023 | 30 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 1 | 2009 | 833 | 0.190 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2025 | 151 | 0.190 |
Why?
|
| Central Venous Pressure | 2 | 2020 | 27 | 0.190 |
Why?
|
| Anticoagulants | 4 | 2019 | 455 | 0.190 |
Why?
|
| Health Status Disparities | 1 | 2025 | 218 | 0.180 |
Why?
|
| Body Mass Index | 1 | 2026 | 806 | 0.180 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2023 | 107 | 0.180 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 55 | 0.180 |
Why?
|
| Mononeuropathies | 1 | 2022 | 8 | 0.180 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 393 | 0.180 |
Why?
|
| Adult | 19 | 2026 | 27849 | 0.180 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 556 | 0.180 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2023 | 186 | 0.170 |
Why?
|
| Time Factors | 8 | 2025 | 5380 | 0.170 |
Why?
|
| Aortic Rupture | 1 | 2022 | 52 | 0.170 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2022 | 98 | 0.170 |
Why?
|
| Aftercare | 1 | 2021 | 89 | 0.160 |
Why?
|
| Arterial Pressure | 2 | 2018 | 41 | 0.160 |
Why?
|
| Lactic Acid | 1 | 2021 | 93 | 0.160 |
Why?
|
| Immunosuppressive Agents | 2 | 2020 | 987 | 0.160 |
Why?
|
| Risk Factors | 8 | 2026 | 5900 | 0.160 |
Why?
|
| Rare Diseases | 1 | 2020 | 71 | 0.160 |
Why?
|
| Antidiuretic Hormone Receptor Antagonists | 1 | 2020 | 27 | 0.160 |
Why?
|
| Mathematical Concepts | 1 | 2020 | 18 | 0.150 |
Why?
|
| Heart | 2 | 2023 | 522 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 1000 | 0.150 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 81 | 0.150 |
Why?
|
| Healthcare Disparities | 1 | 2025 | 496 | 0.150 |
Why?
|
| Electric Impedance | 1 | 2020 | 115 | 0.150 |
Why?
|
| Pulmonary Artery | 2 | 2021 | 333 | 0.150 |
Why?
|
| Sternotomy | 1 | 2019 | 24 | 0.140 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 106 | 0.140 |
Why?
|
| Remote Sensing Technology | 1 | 2018 | 10 | 0.140 |
Why?
|
| Assisted Circulation | 1 | 2018 | 16 | 0.140 |
Why?
|
| Tachycardia, Ventricular | 1 | 2020 | 175 | 0.140 |
Why?
|
| Counterpulsation | 1 | 2018 | 21 | 0.140 |
Why?
|
| Testosterone | 1 | 2019 | 258 | 0.140 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2018 | 56 | 0.140 |
Why?
|
| Enoxaparin | 1 | 2018 | 24 | 0.140 |
Why?
|
| Octreotide | 1 | 2018 | 28 | 0.130 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2018 | 158 | 0.130 |
Why?
|
| Patient Readmission | 2 | 2019 | 403 | 0.130 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2019 | 87 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2022 | 3044 | 0.130 |
Why?
|
| Thermodilution | 1 | 2017 | 18 | 0.130 |
Why?
|
| Risk Assessment | 3 | 2025 | 2434 | 0.130 |
Why?
|
| Endothelium, Vascular | 2 | 2010 | 436 | 0.130 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2025 | 145 | 0.130 |
Why?
|
| Ambulatory Care | 1 | 2018 | 195 | 0.130 |
Why?
|
| Secondary Prevention | 1 | 2018 | 173 | 0.130 |
Why?
|
| Insulin Resistance | 1 | 2019 | 379 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 290 | 0.130 |
Why?
|
| Catheter Ablation | 1 | 2020 | 349 | 0.130 |
Why?
|
| Double-Blind Method | 3 | 2026 | 1727 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 283 | 0.130 |
Why?
|
| Heart Diseases | 1 | 2018 | 258 | 0.120 |
Why?
|
| Kidney Failure, Chronic | 1 | 2020 | 430 | 0.120 |
Why?
|
| Defibrillators, Implantable | 1 | 2018 | 185 | 0.120 |
Why?
|
| Serotonin | 1 | 2016 | 209 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2025 | 58 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 338 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2019 | 1719 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 333 | 0.110 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1193 | 0.110 |
Why?
|
| Incidence | 4 | 2021 | 1697 | 0.100 |
Why?
|
| Gadolinium | 2 | 2026 | 95 | 0.100 |
Why?
|
| Ventricular Remodeling | 2 | 2025 | 99 | 0.100 |
Why?
|
| Peptide Fragments | 2 | 2026 | 468 | 0.100 |
Why?
|
| Hospitalization | 1 | 2019 | 924 | 0.100 |
Why?
|
| Kidney Transplantation | 1 | 2020 | 871 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 762 | 0.090 |
Why?
|
| Prosthesis Design | 3 | 2019 | 293 | 0.090 |
Why?
|
| Hospital Mortality | 2 | 2019 | 480 | 0.090 |
Why?
|
| Carney Complex | 1 | 2012 | 3 | 0.090 |
Why?
|
| Physicians | 1 | 2019 | 668 | 0.090 |
Why?
|
| Lung | 1 | 2018 | 1359 | 0.090 |
Why?
|
| Electrocardiography | 2 | 2015 | 496 | 0.090 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 888 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 371 | 0.090 |
Why?
|
| Sensitivity and Specificity | 3 | 2026 | 1909 | 0.090 |
Why?
|
| Case-Control Studies | 2 | 2025 | 1925 | 0.080 |
Why?
|
| Recurrence | 3 | 2018 | 1188 | 0.080 |
Why?
|
| Decision Trees | 1 | 2010 | 63 | 0.080 |
Why?
|
| Causality | 1 | 2010 | 82 | 0.080 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2010 | 63 | 0.080 |
Why?
|
| Diuretics | 1 | 2010 | 75 | 0.080 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 67 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 96 | 0.070 |
Why?
|
| Reproducibility of Results | 3 | 2026 | 2705 | 0.070 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2009 | 56 | 0.070 |
Why?
|
| Prevalence | 2 | 2024 | 1318 | 0.070 |
Why?
|
| Azathioprine | 1 | 2009 | 122 | 0.070 |
Why?
|
| Prednisone | 1 | 2009 | 242 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2010 | 238 | 0.070 |
Why?
|
| Equipment Failure | 2 | 2018 | 119 | 0.060 |
Why?
|
| Aortic Valve | 2 | 2021 | 250 | 0.060 |
Why?
|
| Drug Therapy, Combination | 1 | 2009 | 753 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2009 | 360 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2019 | 340 | 0.060 |
Why?
|
| Comorbidity | 2 | 2020 | 1003 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2010 | 1519 | 0.060 |
Why?
|
| Disease Progression | 2 | 2021 | 1529 | 0.060 |
Why?
|
| Caribbean Region | 1 | 2025 | 26 | 0.060 |
Why?
|
| Amyloidosis, Familial | 1 | 2023 | 2 | 0.050 |
Why?
|
| Amyloid | 1 | 2024 | 104 | 0.050 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 181 | 0.050 |
Why?
|
| Tricuspid Valve | 1 | 2023 | 94 | 0.050 |
Why?
|
| Technetium Tc 99m Pyrophosphate | 1 | 2022 | 8 | 0.050 |
Why?
|
| Technetium | 1 | 2022 | 21 | 0.050 |
Why?
|
| Diphosphates | 1 | 2022 | 15 | 0.050 |
Why?
|
| Thorax | 1 | 2023 | 77 | 0.050 |
Why?
|
| Societies, Medical | 1 | 2026 | 618 | 0.050 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 269 | 0.050 |
Why?
|
| Graft Survival | 1 | 2026 | 939 | 0.040 |
Why?
|
| ROC Curve | 1 | 2024 | 774 | 0.040 |
Why?
|
| Algorithms | 1 | 2010 | 1948 | 0.040 |
Why?
|
| Propensity Score | 1 | 2022 | 178 | 0.040 |
Why?
|
| Myocardium | 1 | 2024 | 567 | 0.040 |
Why?
|
| Catheterization, Swan-Ganz | 1 | 2021 | 24 | 0.040 |
Why?
|
| Axillary Artery | 1 | 2020 | 12 | 0.040 |
Why?
|
| Heart Atria | 1 | 2022 | 247 | 0.040 |
Why?
|
| Monitoring, Physiologic | 1 | 2021 | 255 | 0.040 |
Why?
|
| Aorta | 1 | 2021 | 273 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2020 | 30 | 0.040 |
Why?
|
| Tissue Donors | 1 | 2023 | 541 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 62 | 0.040 |
Why?
|
| Euthyroid Sick Syndromes | 1 | 2019 | 11 | 0.040 |
Why?
|
| Endocrine System Diseases | 1 | 2019 | 24 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 292 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 366 | 0.040 |
Why?
|
| Hyperthyroidism | 1 | 2019 | 76 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 473 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 136 | 0.040 |
Why?
|
| United States | 2 | 2025 | 7581 | 0.040 |
Why?
|
| Metabolic Diseases | 1 | 2019 | 57 | 0.040 |
Why?
|
| Systole | 1 | 2019 | 81 | 0.040 |
Why?
|
| Heparin | 1 | 2019 | 177 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2022 | 216 | 0.040 |
Why?
|
| Liver | 1 | 2023 | 1206 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2021 | 350 | 0.040 |
Why?
|
| Contrast Media | 1 | 2023 | 986 | 0.030 |
Why?
|
| Operative Time | 1 | 2019 | 167 | 0.030 |
Why?
|
| Coronary Circulation | 1 | 2018 | 95 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2019 | 309 | 0.030 |
Why?
|
| Injections, Intramuscular | 1 | 2018 | 63 | 0.030 |
Why?
|
| Muscle Contraction | 1 | 2019 | 255 | 0.030 |
Why?
|
| International Normalized Ratio | 1 | 2018 | 37 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 158 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2018 | 188 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 116 | 0.030 |
Why?
|
| Neutropenia | 1 | 2018 | 209 | 0.030 |
Why?
|
| Thyroxine | 1 | 2019 | 386 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2010 | 679 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2019 | 275 | 0.030 |
Why?
|
| Risk | 1 | 2018 | 651 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 354 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 688 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 29 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 753 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2018 | 177 | 0.030 |
Why?
|
| Illinois | 1 | 2018 | 515 | 0.030 |
Why?
|
| Reoperation | 1 | 2019 | 696 | 0.030 |
Why?
|
| Gastrointestinal Agents | 1 | 2018 | 181 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2026 | 2562 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 116 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1518 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 603 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 874 | 0.030 |
Why?
|
| Chicago | 1 | 2019 | 1452 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 271 | 0.030 |
Why?
|
| Equipment Design | 1 | 2016 | 411 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 151 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 984 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 1171 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 570 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 873 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 3450 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1908 | 0.030 |
Why?
|
| Sex Factors | 1 | 2016 | 1102 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2017 | 626 | 0.020 |
Why?
|
| Age Factors | 1 | 2016 | 1898 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 1073 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 2787 | 0.020 |
Why?
|
| Mutation | 1 | 2022 | 4265 | 0.020 |
Why?
|
| Brachial Artery | 1 | 2010 | 37 | 0.020 |
Why?
|
| Exercise Tolerance | 1 | 2010 | 63 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 228 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2009 | 941 | 0.010 |
Why?
|
| Adolescent | 1 | 2012 | 9550 | 0.010 |
Why?
|